Lymphomas are a diverse group of malignant disorders that include non-Hodgkin's lymphoma and Hodgkin lymphoma. Collectively, lymphomas represent the fifth most common cancer type and the fifth leading cause of cancer death in the US. In 2006, the American Cancer Society estimates that more than 66 000 individuals in the US will be diagnosed with lymphoma, the majority of which (88%) will be classified as non-Hodgkin's lymphoma. Although enormous progress in cancer biology has been made over the past few decades, resulting in an overall decrease in the frequency of most cancers, the incidence of lymphomas continues to increase unabated. Clearly, an urgent need exists for newer and more effective treatments for these diseases. Far too many years have been spent combining existing cytotoxic drugs with only limited success.
In general terms, current cancer treatment strategies are tending to move away from nonspecific cytotoxic agents to biologically targeted drugs with more specific mechanisms of antitumour action. This approach is especially true for the management of non-Hodgkin's lymphoma, whose cancer cells can be targeted with greater reliability. One such group of targeted chemotherapeutic agents is the histone deacetylase (HDAC) inhibitors, which promote gene transcription by decreasing binding of histones to DNA and thereby produce growth arrest and apoptosis in cancer cells. Histone deacetylases have been implicated in the pathogenesis of lymphomas via regulation of the BCL-6 gene and, thus, their inhibition may provide a unique target for antilymphoma therapy.
One promising new weapon in our armamentarium to treat patients with lymphomas is the HDAC inhibitor vorinostat (suberoylanilide hydroxamic acid or SAHA). This supplement highlights our current understanding of the antitumour effects of vorinostat and reviews our clinical experience to date on the use of vorinostat in treating advanced haematological malignancies, including Hodgkin's disease and select subtypes of non-Hodgkin's lymphoma. The three articles comprising this supplement are Collectively, these presentations provide encouraging data on the potential clinical efficacy of vorinostat as a single therapeutic modality in treating patients with lymphomas. Such data as are presented in this volume have led, in part, to the recent approval of this agent by the US Food and Drug Administration for the treatment of patients with relapsed or refractory CTCL. Undoubtedly, however, the greatest benefit from this agent will be as part of multidrug regimens. The rational combination of vorinostat with agents that have complementary mechanisms of antitumour action may ultimately lead to optimisation of chemotherapy regimens for lymphoma patients and perhaps lead to a reduction in our dependence on the more toxic, nonspecific cytotoxic agents. Combination therapies incorporating vorinostat are likely to contribute greatly to our increased ability to cure patients with lymphomas and may herald a new era in cancer therapy.
